XML 44 R37.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Disaggregation Of Revenue [Line Items]        
Revenue $ 71,553 $ 58,879 $ 142,427 $ 111,322
MRD Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 66,168 49,938 133,261 93,659
MRD Revenue | Service Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 66,168 44,438 124,261 83,659
MRD Revenue | Regulatory Milestone Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 0 5,500 9,000 10,000
Immune Medicine Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 5,385 8,941 9,166 17,663
Immune Medicine Revenue | Service and Licensing Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue 5,385 5,001 9,166 10,123
Immune Medicine Revenue | Collaboration Revenue        
Disaggregation Of Revenue [Line Items]        
Revenue [1] $ 0 $ 3,940 $ 0 $ 7,540
[1] On August 13, 2025, the Genentech Agreement was terminated, with termination effective February 9, 2026.